|
"saijo n"的相关文件
显示项目 1-8 / 8 (共1页)
1
每页显示[10|25|50]项目
| 臺大學術典藏 |
2020-05-26T09:27:19Z |
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
|
Mok T.S; Wu Y.-L; Thongprasert S; Yang C.-H; Chu D.-T; Saijo N; Sunpaweravong P; Han B; Margono B; Ichinose Y; Nishiwaki Y; Ohe Y; CHIH-HSIN YANG; Chewaskulyong B; Jiang H; Duffield E.L; Watkins C.L; Armour A.A; Fukuoka M. |
| 臺大學術典藏 |
2020-05-26T09:27:15Z |
Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)
|
Thongprasert S;Duffield E;Saijo N;Wu Y.-L;Chih-Hsin Yang;Chu D.-T;Liao M;Chen Y.-M;Kuo H.-P;Negoro S;Lam K.C;Armour A;Magill P;Fukuoka M.; Thongprasert S; Duffield E; Saijo N; Wu Y.-L; CHIH-HSIN YANG; Chu D.-T; Liao M; Chen Y.-M; Kuo H.-P; Negoro S; Lam K.C; Armour A; Magill P; Fukuoka M. |
| 臺大學術典藏 |
2020-05-26T09:27:11Z |
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
|
Fukuoka M;Wu Y.-L;Thongprasert S;Sunpaweravong P;Leong S.-S;Sriuranpong V;Chao T.-Y;Nakagawa K;Chu D.-T;Saijo N;Duffield E.L;Rukazenkov Y;Speake G;Jiang H;Armour A.A;To K.-F;Chih-Hsin Yang;Mok T.S.K.; Fukuoka M; Wu Y.-L; Thongprasert S; Sunpaweravong P; Leong S.-S; Sriuranpong V; Chao T.-Y; Nakagawa K; Chu D.-T; Saijo N; Duffield E.L; Rukazenkov Y; Speake G; Jiang H; Armour A.A; To K.-F; CHIH-HSIN YANG; Mok T.S.K. |
| 臺大學術典藏 |
2020-05-26T09:27:01Z |
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
|
Wu Y.-L;Fukuoka M;Mok T.S.K;Saijo N;Thongprasert S;Chih-Hsin Yang;Chu D.-T;Chih-Hsin Yang;Rukazenkov Y.; Wu Y.-L; Fukuoka M; Mok T.S.K; Saijo N; Thongprasert S; CHIH-HSIN YANG; Chu D.-T; CHIH-HSIN YANG; Rukazenkov Y. |
| 臺大學術典藏 |
2020-05-26T09:26:58Z |
Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III iressa pan-ASia study (IPASS)
|
Chih-Hsin Yang;Wu Y.-L;Chan V;Kurnianda J;Nakagawa K;Saijo N;Fukuoka M;Mcwalter G;Mccormack R;Mok T.S.K.; CHIH-HSIN YANG; Wu Y.-L; Chan V; Kurnianda J; Nakagawa K; Saijo N; Fukuoka M; McWalter G; McCormack R; Mok T.S.K. |
| 臺大學術典藏 |
2020-05-26T09:26:40Z |
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
|
Fukuoka M.;Rukazenkov Y;Haddad V;Young H;Mok T.S.K;Yang J.-J;Ichinose Y;Ohe Y;Sunpaweravong P;Chewaskulyong B;Margono B;Han B;Chih-Hsin Yang;Thongprasert S;Saijo N;Wu Y.-L; Wu Y.-L; Saijo N; Thongprasert S; CHIH-HSIN YANG; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang J.-J; Mok T.S.K; Young H; Haddad V; Rukazenkov Y; Fukuoka M. |
| 臺大學術典藏 |
2018-09-10T08:44:19Z |
International association for the study of lung cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma
|
Brambilla, E.; Noguchi, M.; Nicholson, A.G.; Geisinger, K.R.; Yatabe, Y.; Beer, D.G.; Powell, C.A.; Riely, G.J.; Van Schil, P.E.; Garg, K.; Austin, J.H.M.; Asamura, H.; Rusch, V.W.; Hirsch, F.R.; Scagliotti, G.; Mitsudomi, T.; Huber, R.M.; Ishikawa, Y.; Jett, J.; Sanchez-Cespedes, M.; Sculier, J.-P.; Takahashi, T.; Tsuboi, M.; Vansteenkiste, J.; Wistuba, I.; Yang, P.-C.; Aberle, D.; Brambilla, C.; Flieder, D.; Franklin, W.; Gazdar, A.; Gould, M.; Hasleton, P.; Henderson, D.; Johnson, B.; Johnson, D.; Kerr, K.; Kuriyama, K.; Lee, J.S.; Miller, V.A.; Petersen, I.; Roggli, V.; Rosell, R.; Saijo, N.; Thunnissen, E.; Tsao, M.; Yankelewitz, D.; Travis, W.D.; PAN-CHYR YANGet al. |
| 國立臺灣大學 |
2015 |
Efficacy by blind independent central review (BICR): Post hoc analyses of the phase III, multicentre, randomised IPASS study of 1st-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in Asian patients (pts) with EGFR mutation-positive advanced NSCLC
|
Mok, T.; Saijo, N.; Thongprasert, S.; Yang, J. C. -H.; Wu, Y. -L.; Young, H.; Haddad, V.; Jiang, H.; Fukuoka, M.; 楊志新 |
显示项目 1-8 / 8 (共1页)
1
每页显示[10|25|50]项目
|
